1. Home
  2. SEV vs TTRX Comparison

SEV vs TTRX Comparison

Compare SEV & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SEV

Aptera Motors Corp.

HOLD

Current Price

$2.14

Market Cap

103.2M

Sector

Industrials

ML Signal

HOLD

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$5.82

Market Cap

107.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEV
TTRX
Founded
2019
2015
Country
United States
United States
Employees
46
2
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.2M
107.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SEV
TTRX
Price
$2.14
$5.82
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
228.4K
52.4K
Earning Date
05-16-2026
05-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$17,757.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.29
$2.57
52 Week High
$11.24
$6.75

Technical Indicators

Market Signals
Indicator
SEV
TTRX
Relative Strength Index (RSI) 28.63 65.47
Support Level $1.29 $3.92
Resistance Level $3.26 N/A
Average True Range (ATR) 0.17 0.55
MACD -0.02 0.12
Stochastic Oscillator 0.00 63.93

Price Performance

Historical Comparison
SEV
TTRX

About SEV Aptera Motors Corp.

Aptera Motors Corp engages in the development, production, and distribution of energy efficient solar-powered, battery-electric vehicles. The company has designed the Aptera vehicle to provide up to an estimated 40 miles per day by collecting energy from the sun and storing it in its proprietary battery pack. The company operates as a single reportable segment focused on the development of solar electric vehicles.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: